If CD19 is used in tangent with Kappa/Lambda antibodies, the Kappa+ or Lambda+ B cells can be identified even with cytophilic Ig present on the cells. We routinely run 3-color 19/Kappa/Lambda, but do not routinely add FCS to all our leukemias/lymphomas. Does question 11.3072 on the CAP checklist mean that all leukemias/lymphomas should be pre-treated?
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:50:16 EST